Loading...
•
Dec 31, 2020
Verona Pharma Q4 2020 Earnings Report
Verona Pharma's financial results for Q4 2020 and corporate updates were reported.
Key Takeaways
Verona Pharma reported its financial results for the fourth quarter and full year ended December 31, 2020, along with a corporate update, highlighting positive Phase 2 results and ongoing Phase 3 program enrollment.
Positive Phase 2 results with pMDI ensifentrine in COPD were achieved.
Enrollment is ongoing in the ENHANCE Phase 3 program.
A debt finance facility of up to $30 million was secured, increasing financial flexibility.
A conference call was hosted to discuss the fourth quarter and full year 2020 financial results and corporate update.
Forward Guidance
Verona Pharma anticipates top-line data from the pilot COVID-19 study of ensifentrine in the second quarter of 2021 and expects to complete enrollment in the ENHANCE program in the second half of 2021. Top-line data from ENHANCE-2 is expected in the first half of 2022 and from ENHANCE-1 in the second half of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...